Concise Review: Generation of Neurons From Somatic Cells of Healthy Individuals and Neurological Patients Through Induced Pluripotency or Direct Conversion

IVAN VELASCO, a,b PATRICIA SALAZAR, a,b ALESSANDRA GIORGETTI, c VERÓNICA RAMOS–MEJIA, b JULIO CASTANO, c DAMIA ROMERO–MOYA, c VEROÑICA RAMOS–MEJIA, b

Key Words. Induced pluripotent stem cells • Neural differentiation • Induced neurons • Direct conversion • Neurodegenerative diseases • Genome editing

ABSTRACT

Access to healthy or diseased human neural tissue is a daunting task and represents a barrier for advancing our understanding about the cellular, genetic, and molecular mechanisms underlying neurogenesis and neurodegeneration. Reprogramming of somatic cells to pluripotency by transient expression of transcription factors was achieved a few years ago. Induced pluripotent stem cells (iPSCs) from both healthy individuals and patients suffering from debilitating, life-threatening neurological diseases have been differentiated into several specific neuronal subtypes. An alternative emerging approach is the direct conversion of somatic cells (i.e., fibroblasts, blood cells, or glial cells) into neuron-like cells. However, to what extent neuronal direct conversion of diseased somatic cells can be achieved remains an open question. Optimization of current expansion and differentiation approaches is highly demanded to increase the differentiation efficiency of specific phenotypes of functional neurons from iPSCs or through somatic cell direct conversion. The realization of the full potential of iPSCs relies on the ability to precisely modify specific genome sequences. Genome editing technologies including zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeat/CAS9 RNA-guided nucleases have progressed very fast over the last years. The combination of genome-editing strategies and patient-specific iPSC biology will offer a unique platform for in vitro generation of diseased and corrected neural derivatives for personalized therapies, disease modeling and drug screening. Stem Cells 2014;32:2811–2817

INDUCED PLURIPOTENCY

Pluripotency is defined by the ability to produce from a single undifferentiated cell type, cell derivatives representing the three germ layers: meso-, endo-, and ectoderm. Pluripotent stem cells (PSCs) of human origin were first isolated from teratocarcinomas, giving rise to embryonal carcinoma cell lines [1]. This property is expected to be present in cells giving rise to gametes during human development and thus, pluripotent embryonic germ cells were described in 1998 [2]. The most widely used PSCs of mammalian origin are mouse embryonic stem cells (ESCs), derived from the inner cell mass of preimplantation embryos at the blastocyst stage [3, 4]. Using a similar approach, human ESCs (hESCs) were isolated from embryos almost 2 decades later [5]. During human development, germline cells undergo meiosis to produce gametes. The remaining cellular types are known as somatic cells, and they do not contribute to reproductive tissues. Early work has shown that misexpression of MyoD can convert cell fate between germ layers [6, 7]. Similarly, ectopic expression of master lineage-specific transcriptional regulators allows cells to change from one blood lineage to another [8]. However, it was not recognized until recently how relatively easy it is for a terminally differentiated somatic cell to re-acquire pluripotency properties or change cell fate across germ layers.

Successful reprogramming of somatic cells to a pluripotent state by transient expression of four transcription factors (OCT4, SOX2, KLF4, and c-MYC) was achieved for the first time with mouse cells in 2006 [9] and with human fibroblasts in 2007 [10, 11] using retroviral vectors. Many researchers have produced induced pluripotent stem cells (iPSCs) by expressing the Yamanaka factors through integrative or nonintegrative methods. Among the former, retroviral and lentiviral vectors are the...
most widely used [12]. Induced pluripotency requires endogenous activation of a pluripotency-associated gene expression signature and a concomitant silencing of ectopic reprogramming factors. Genomic integration of these transgenes is random and becomes epigenetically regulated so that their residual expression after long-term culture due to a lack of complete silencing may prevent subsequent differentiation [13] and make iPSCs prone to genomic alterations [14]. The most common nonintegrative methodologies include Sendai virus (SeV) [15], mRNA [16], plasmid DNA [17], or introduction of the recombinant proteins into somatic cells [16]. Also, small molecules [18] can substitute some reprogramming genes. Interestingly, microRNAs (miR) [19, 20] can produce iPSCs on their own, without the pluripotency reprogramming genes. It is especially relevant the ability of miR-302 to contribute to iPSCs generation, which is in line with the well-established role of miR-302 as a key regulator of pluripotency in hESCs [21–25].

However, the generation of iPSCs is still inefficient, yielding a low proportion of reprogrammed cells [18]. Many small molecules and epigenetic remodeling drugs have been reported to increase iPSC efficiency [26]. However, how these ectopic factors can make a somatic cell to travel back in development and become pluripotent through epigenetic reprogramming remains elusive. Cellular reprogramming is assumed to be a stressful cellular process. In fact, during the reprogramming process several genomic insults including coding mutations, insertions/deletions (indels), and chromosomal rearrangements occur. This genomic instability may activate the DNA damage response (DDR) which may in turn contribute to a selection of specific clones during reprogramming to pluripotency [27–29]. Also, whether or not induced pluripotency is a purely stochastic process remains controversial [30]. There are important regulators of this process, such as p53 [31–33] and Mbd3. Indeed, inhibition of Mbd3 allowed a reprogramming efficiency of almost 100% [34]. Recently, differences in cell cycle length allowed the identification of rapid-cycling cells as responsible for the bulk of reprogrammed cells [35]. Together, although many technical and biological questions about the cellular, molecular, and epigenetic mechanisms underlying reprogramming remain elusive, making induced reprogramming an obscure and low efficient process, human iPSCs (hiPSCs) have revolutionized biomedical research opening up unprecedented avenues in developmental biology, drug screening, and disease modeling. Because access to healthy or diseased human neural tissue is a challenge and limits our understanding on neurogenesis and neurodegeneration, diseases affecting the central nervous system might particularly benefit from iPSC biology.

NEURAL DIFFERENTIATION OF PSCS

Several protocols for neuronal differentiation of human PSCs, including iPSCs, have been reported. Neural commitment of PSCs can be achieved through formation of embryoid bodies and treatment with retinoic acid or inhibition of transforming growth factor-β and bone morphogenic proteins (dual SMAD inhibition), followed by expansion of neural stem/progenitor cells in monolayer or neurosphere cultures. Alternatively, fibroblasts, cord blood cells, or astrocytes can be directly converted to neurons, either in vitro or in vivo. Abbreviations: miRNAs, microRNAs; iPSC, induced pluripotent stem cell.
instance, motor neuron differentiation of hESCs and hiPSCs has been refined to a point that spinal lateral column phenotypes can be obtained [36, 41]. Similarly, for dopaminergic neurons, midbrain phenotypes can be successfully produced in high yields from hESCs and hiPSCs [38, 39]. These human PSC (hiPSC)-derived neurons were transplanted in animal models of neurological disease where survived and contributed to the partial recovery of several neurological parameters, including behavior. These results should encourage us to further explore hPSC-derived neurons in preclinical settings [42]. Beyond potential cell therapy applications, hiPSC-derived neurons open up new avenues in drug screening and disease modeling applications.

Induced PSCs have been generated from biopsies of patients harboring mutations associated to amyotrophic lateral sclerosis [41], spinal muscular atrophy [43, 44], Parkinson disease [45, 46], Alzheimer disease [47], and Rett syndrome [48]. Some of these patient/disease-specific iPSCs give rise, under proper inductive conditions, to the affected neuronal subtype, opening up new avenues to explore: (a) the potential of these neurons to graft the patient in an autologous setting, provided the procedure is safe and effective, (b) the in vitro neuronal differentiation of mutated iPSC as a disease model to unravel the developmental, cellular, and molecular mechanisms underlying the disease onset and progression, and (c) large-scale drug screening aimed at restoring impaired functions or preventing neuronal degeneration. In fact, long-term culture of dopamine neurons differentiated from mutant Parkinson hiPSCs showed increased apoptosis and decreased number and shorter neurites [45]. In another study, Parkinson patient-specific iPSC were generated and differentiated into neural derivatives that were challenged with mitochondrial stressors, revealing an increased susceptibility as compared to neural cells from control iPSCs. Furthermore, supplementation of the culture medium with the antioxidant coenzyme Q10 or rapamycin caused partial protection against neural degeneration [49]. These studies underscore the potential of iPSCs and iPSC-neural derivatives to gain insights into the underlying mechanisms of neurodegeneration and to explore them as a biological platform to screen potential therapeutic molecules, eventually contributing to the development of novel pharmacological approaches.

Collections of patient/disease-specific hiPSCs, including neurological conditions [50], will be of utmost value to advance our understanding of the disease. Furthermore, an initiative for public banking of diseased fibroblasts from patients with mutations related to neurodegenerative diseases is already ongoing [51]. It will be important to consider both sporadic and familial forms of neurological diseases to allow comparisons among patients and mutations in order to identify common and distinct mechanisms underlying the disease pathogenesis as well as wide-acting drugs. However, the generation of functional neurons from hiPSCs, namely cells that express markers of neuronal differentiation (β-III tubulin, microtubule associated protein-2, or NeuN), fire action potentials, synthesize and release neurotransmitters and form synapses with neighboring neurons, often requires extended periods of culture and the available protocols are complex and suffer from high variability. Recently, lineage priming to neurons from hESCs and iPSCs was induced by forced expression of a single transcription factor (either NEUROGENIN-2 or NEUROD1) which resulted in the emergence of mature neurons within 2 weeks, speeding up significantly the time required to obtain mature human neurons in vitro [52]. Besides differentiation efficiency, a homogeneous population of lineage-specific cells (i.e., neuronal populations) from hPSCs must be eventually obtained to prevent the presence in the culture of residual undifferentiated cells which may exert undesired/misleading effects both in vitro and in vivo.

### DIRECT CONVERSION OF SOMATIC CELLS INTO NEURONS

After the seminal reprogramming work of Yamanaka and coworkers, other investigators started testing the hypothesis that expression of transcriptional regulators might act as neural cell determinants to non-neural differentiated somatic cells. Indeed, ectopic expression of ASCL1, BRN2A, and MYT1L turned fibroblasts directly (no pluripotent stage involved) into induced neurons (iNs) [53, 54] (Fig. 1). Expression of additional neural lineage-specific transcriptional regulators further promoted the conversion of human fibroblasts into dopamine [55, 56] and motor neurons [57]. Interestingly, although this direct conversion into iNs rarely requires the neural progenitor state, human fibroblasts can also be induced by the sole expression of SOX2 to become multipotent neural stem cells, able to differentiate into neurons, astrocytes, and oligodendroglia [58]. Direct conversion of fibroblasts into iNs usually requires a skin biopsy that is expanded in culture to generate enough starting material. Therefore, the use of a more accessible source in medical diagnostic procedures, such as blood, would be highly advantageous. In fact, cord blood stem cells have been recently reprogrammed into iNs by forced expression of SOX2 and c-MYC [59]. This work showed for the first time that cells from mesodermal origin can be switched to an ectodermal fate with only two transcription factors. The procedure for generating iNS relies on the use of integrative vectors, and similar to the production of hiPSCs, is rather complex and inefficient. Recently, some progress has been made in direct reprogramming of non-human primate fibroblasts into region-specific neural progenitors through transient expression of the four Yamanaka factors using nonintegrative SeV in combination with specific neural culture conditions [60]. These results represent an important technical progress for the generation of iNS, although the presence of a pluripotent intermediate cellular stage cannot be ruled out in these experiments, and the process continues to be quite inefficient. Because SeV vectors seem to be one of the most efficient nonintegrative strategies for reprogramming blood cells to iPSCs [61, 62] it will be of interest to determine if delivery of SOX2 and c-MYC by means of SeV transduction might enhance the direct reprogramming efficiency of blood cells into iNS. Blood-derived iNS could provide a unique tool for drug screening and will facilitate the development of a cellular platform for the generation of patient-specific neuronal cells for future biomedical applications.

Direct conversion of non-neural cells into neurons is also possible in vivo. Human fibroblasts or astrocytes engineered to express doxycycline-inducible ASCL1, BRN2A, and MYT1L are converted into neurons within the rodent brain after doxycycline addition. Interestingly, endogenous brain astrocytes were also converted into iNS highlighting a specie-
independent direct conversion [63]. In a similar approach, NeuroD1 transduction of reactive astrocytes and oligodendrocytes present after acute brain damage or as a consequence of a chronic damage in a transgenic Alzheimer disease mouse model also rendered iNs in vivo. Notably, astrocyte-derived iNS mainly produced glutamatergic neurons whereas oligodendrogyte-derived iNs generated both glutamatergic and gabaergic neurons [64]. To what extent neuronal direct conversion is possible in other diseased somatic non-neural cells remains an open question. While these results are promising, the field has yet to clearly address how much these iNs resemble to neurons/neural progenitors and whether iNs retain epigenetic memory; that is, they retain gene expression and epigenetic profiles similar to the donor cell type (fibroblasts, hematopoietic cells and astrocytes) that was originally reprogrammed. This epigenetic memory is crucial since it may influence subsequent differentiation potential. Taken together, integration of technical and biological expertise gained from hiPSCs and hiNs will boost our ability to move the field forward facilitating the implementation of disease modeling and drug screening applications. Eventually, the realization of the full potential of iPSCs/iNs relies on the ability to improve the reprogramming/direct conversion and combine efficient differentiation protocols with the precise modification of specific genome sequences.

Importantly, genome editing in hPSCs has evolved from being a daunting task to a widely spread procedure in worldwide laboratories. The reasons for this are twofold: (a) human PSCs are especially amenable for genome editing since they can undergo extensive culture manipulations, such as drug selection and clonal expansion, while still maintaining their pluripotency and genome stability [66], and (b) genome editing technology has progressed extremely rapid over the last few years including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), clustered regularly interspaced short palindromic repeat/CAS9 RNA-guided nucleases (CRISPR/CAS9) (Table 1), and helper-dependent adenoviral vectors (HDAdVs). An important aspect is that cells that have undergone genome editing should contain only the intended change in an otherwise isogenic background, thus providing the most stringent test of gene function. However, this may not be the case due to off-target effects of ZFNs, TALENs, and CRISPR/CAS9. However, these genome-editing tools are under continuous improvement [67, 68]. The biological mechanisms underlying these genome-editing tools in human PSCs cannot be covered in this review due to space constrains, but they have been extensively and elegantly reviewed elsewhere [66]. Table 1 summarizes the differential biological and technical features of cutting-edge main genome-editing approaches. Although only a minority of the neurodegenerative diseases is caused by a specific identified mutation, there are examples showing the potential of genome editing in iPSC for neurological diseases.

Huntington disease is caused by expansion of a polyglutamine motif in HUNTINGTIN. Through homologous recombination in iPSCs, the number of glutamines in this protein was reduced, resulting in decreased apoptosis and improvement in oxygen consumption rate in corrected neural progenitors [69]. Spinal muscular atrophy is a genetic autosomal recessive disease caused by mutations of the SMN1 gene which results in a nonfunctional protein causing motor neuron

**Figure 2.** Cartoon depicting the strategy for combining genome editing and patient-specific human iPSCs (hiPSCs) for in vitro generation of diseased and corrected lineage-specific derivatives for disease modeling and drug screening. Studies on disease modeling and drug screening should be undertaken in parallel on both diseased and genetically corrected cell lines. Due to the high variability existing among hiPSC lines derived from distinct starting cells, using different methods, and from different genetic backgrounds, the use of an isogenic mutation-corrected iPSC line is essential as a control. Abbreviations: CRISPR/CAS9, clustered regularly interspaced short palindromic repeat/CAS9 RNA-guided nucleases; HDAdV, helper-dependent adenoviral vectors; iPSCs, induced pluripotent stem cells; TALENs, transcription activator-like effector nucleases; ZFN, zinc finger nucleases.
degeneration. As a compensatory mechanism, these patients rely on the expression of SMN2, which is highly homologous to SMN1 but has a change in a nucleotide that alters its splicing, with a consequent reduction in the amount of SMN produced. Using single-stranded DNA sequences, editing of the SMN2 was performed, resulting in a SMN1-like protein that includes the exon 7. This change was shown to be stable and correlated with increased motor neuron survival in repaired cells [43]. Recently, ZFN-mediated genome editing and iPSC technology were combined to generate sets of isogenic diseased and control hiPSCs that differ exclusively at either of two susceptibility variants for Parkinson’s disease by modifying the underlying point mutations in the α-synuclein gene [46]. In addition, a point mutation related to familial Parkinson has been corrected using HDAdVs. Notably, these diseased hiPSCs produced neural stem cells that showed alterations in the nuclear architecture, a finding that was not previously reported as related to this pathology. Genetic correction of hiPSCs resulted in normalization of the nuclear alterations, decreased susceptibility to apoptosis, as well as increased neuronal production [70]. The robust capability to genetically correct Parkinson disease-causing point mutations in patient-derived hiPSCs represents a noteworthy progress in basic neurosciences, and a significant advance toward hiPSC-based cell replacement therapies and drug testing. Whether or not the corrected neurons will survive after transplantation in the altered central nervous system (environment) represents a next level of complexity that still needs to be addressed.

**CONCLUSION**

Over the last decade we have witnessed significant progress in both our understanding of cell fate determinants and also in the possibilities to use reprogramming in the preclinical setting. The generation of human neurons by these methodologies will definitively allow the analysis of the mechanisms causing familial and sporadic cases of neurological conditions. Patients therefore can benefit from in vitro differentiated neurons and specific drugs identified by high-throughput screening. If genome editing turns out to be safe and effective, we envision a future prospective production of clinically relevant neuronal types within the brain of affected people. Whether or not the synaptic communication will be re-established properly in the diseased brain is a different question, but repopulation of the affected neuronal phenotype, either by transplantation of differentiated neurons or by direct conversion of resident glial cells is a very encouraging step forward.

**ACKNOWLEDGMENTS**

This work was supported by the E-Rare-ERA-NET/ISCIII (PI12/03112) and the MINECO (SAF2013–43065) to P.M. I.V. was supported by Conacyt (sabbatical fellowship in P.M. lab and CB-131281) and Dirección General de Asuntos de Personas Académicas (PASPA and PAIPII IN208713), Universidad Nacional Autónoma de México. D.R.-M. was supported by PFIS scholarship (F111/0511). P.M. also acknowledges the financial support of the Obra Social La Caixa-Fundació Josep Carreras, Spanish Association against Cancer and Fundación Sandra Ibarra.

**AUTHOR CONTRIBUTIONS**

All the authors contributed to conception and design, data collection and assembly, and manuscript writing. All authors approved submission.

**DISCLOSURE OF POTENTIAL CONFLICT OF INTEREST**

The authors indicate no potential conflict of interest.
and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
10. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872.
11. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1912–1920.
12. Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol Biol 2013;997:23–33.
13. Ramos-Mejía V, Montes R, Bueno C et al. Residual expression of the reprogramming factors prevents differentiation of iPS cells generated from human fibroblasts and cord blood CD34+ progenitors. PLoS One 2012;7:e35824.
14. Ramos-Mejía V, Munoz-Lopez M, Garcia-Perez JL et al. ipSCs that do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability. Cell Res 2010;20:1092–1095.
15. Nakanishi M, Otsu M. Development of embryonic stem cell differentiation. EMBO J 2011;30:237–248.
16. Onder TT, Kara N, Cherry A et al. Chromatin-modifying enzymes as modulators of reprogramming. Cell 2012;148:598–602.
17. Gore A, Li Z, Fung HL et al. Sonic condensers in human induced pluripotent stem cells. Nature 2011;471:63–67.
18. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471:58–62.
19. Pasi CE, Delerel-Oz A, Negrini S et al. Genomic instability in induced stem cells. Cell Death Differ 2011;18:745–753.
20. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell 2010;143:508–525.
21. Hong H, Takahashi K, Ichisaka T et al. Suppression of induced pluripotent stem cell generation by the p53 p21 pathway. Nature 2009;460:1132–1135.
22. Kawamura T, Suzuki J, Wang YV et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460:1140–1145.
23. Marion RM, Strati K, Li H et al. A p53-mediated DNA damage response limits reprogramming to ensure iPSC cell genomic integrity. Nature 2009;460:1149–1153.
24. Rais Y, Zviran A, Geula S et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 2011;502:65–70.
25. Guo S, Zhi X, Schulz VP et al. Nonstochastic reprogramming from a privileged somatic cell state. Cell 2014;156:649–662.
26. Amoroso MW, Croft GF, Williams DJ et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci 2013;33:574–586.
27. Ercog S, Ronaghi M, Zipanic I et al. Efficient differentiation of human embryonic stem cells into functional corticobasal-like cells. Stem Cells Dev 2010;19:1745–1756.
28. Jaeger J, Arber C, Risner-Janicek JR et al. Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells. Development 2011;138:4363–4374.
29. Kriks S, Shim JW, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraf in animal models of Parkinson’s disease. Nature 2011;480:547–551.
30. Maroof AM, Keros S, Tyson JA et al. Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell 2013;12:559–572.
31. Dimos JT, Rodofka KT, Niakan KK et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218–1221.
32. Lopez-Gonzalez R, Velasco I. Therapeutic potential of motor neurons differentiated from embryonic stem cells and induced pluripotent stem cells. Arch Med Res 2012;43:1–10.
33. Corti S, Nizzardo M, Simone C et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med 2012;4:156ra162.
34. Ebert AD, Yu J, Rose FF, Jr. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277–280.
35. Sanchez-Danes A, Richard-Patin Y, Carballo-Carbajal I et al. Disease-specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 2012;4:380–395.
36. Soldner F, Laganiere J, Cheng AW et al. Generation of isogenic pluripotent stem cell derived exclusively at two early onset Parkinson’s disease mutations. Cell 2011;146:318–331.
37. Israel MA, Yuan SH, Bardy C et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 2012;482:216–220.
38. Marchetto MC, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527–539.
39. Cooper O, Seo H, Andrabi S et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med 2012;4:141ra130.
40. Park H, Arora N, Hsu H et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877–886.
41. Wray S, Self M, Consortium NPdS et al. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One 2012;7:e34039.
42. Zhang Y, Pak C, Han Y et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuro 2013;78:785–798.
43. Pang ZP, Yang N, Vierbuchen T et al. Induction of human neuronal cell by transcription factors. Nature 2011;476:220–223.
44. Vierbuchen T, Ostermeier A, Pang ZP et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010;463:1035–1041.
45. Caiazzo M, Dell’Anno MT, Dvoretckova E et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011;476:224–227.
46. Pfenninger U, Kirkeby A, Torpe O et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci USA 2011;108:10343–10348.
47. Son ET, Ichida JK, Wainger BJ et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 2011;9:205–218.
48. Ring KL, Tong LM, Balestra ME et al. Direct reprogramming of mouse and human fibroblasts into multipotent neuronal stem cells with a single factor. Cell Stem Cell 2012;11:100–109.
49. Giorgetti A, Marchetto MC, Li M et al. Cord blood-derived neuronal cells by ectopic expression of Sox2 and c-Myc. Proc Natl Acad Sci USA 2012;109:12556–12561.
50. Lu J, Liu H, Huang CT et al. Generation of integration-free and region-specific neural progenitors from primate fibroblasts. Cell Rep 2013;3:1580–1591.
51. Ban H, Nishisaka M, Fusaki N et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors.
62 Merling RK, Sweeney CL, Choi U et al. Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 2013;121:e98–107.

63 Torper O, Pfisterer U, Wolf DA et al. Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci USA 2013;110:7038–7043.

64 Guo Z, Zhang L, Wu Z et al. In Vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell 2014;14:188–202.

65 Simara P, Motl JA, Kaufman DS. Pluripotent stem cells and gene therapy. Transl Res 2013;161:284–292.

66 Li M, Suzuki K, Kim NY et al. A cut above the rest: Targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 2014;289:4594–4599.

67 Shen B, Zhang W, Zhang J et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods 2014;11:399–402.

68 Wu Y, Gao T, Wang X et al. TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus. Biochem Biophys Res Commun 2014;446:261–266.

69 An MC, Zhang N, Scott G et al. Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11:253–263.

70 Liu GH, Qu J, Suzuki K et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012; 491:603–607.